POMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements
Both market-value deficiencies carry 180-calendar-day compliance periods, with a potential delisting notification if they remain unresolved.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pomdoctor (Nasdaq: POM) received two Nasdaq notices on October 28, 2026, identifying deficiencies in its continued listing requirements.
Over 30 consecutive business days from September 16 through October 27, 2026, its market value of listed securities failed the $50 million minimum, and its market value of publicly held shares failed the $15 million minimum. Nasdaq also identified noncompliance with Rule 5450(b)(3)(A).
The company has until April 26, 2027, to regain compliance. Each market value must close at or above its respective minimum for at least ten consecutive business days. Failure to regain compliance within the applicable period would result in a delisting notification. Pomdoctor intends to monitor both values and evaluate available options.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- None.
Negative
- Major pointListed-securities market value failed Nasdaq’s $50 million minimum over 30 consecutive business days ending October 27, 2026.
- Major pointPublicly held shares’ market value failed Nasdaq’s $15 million minimum over the same 30-business-day period.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Delisting notification would follow failure to regain compliance by April 26, 2027.
- Minor pointNasdaq Rule 5450(b)(3)(A) requirements also remain unmet.
Details
Market move: POM -6.00% vs previous close. Nasdaq listing deficiency
On Nov 2, the day this news came out, the latest delayed price for POM is 6.00% below the previous close. Our momentum scanner has recorded 36 alerts for this stock so far that day. The latest delayed price is $1.74. Relative volume is very high at 4.3x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- MVLS minimum
- $50 million
- Continued listing threshold the company no longer met
- MVPHS minimum
- $15 million
- Publicly held shares threshold the company no longer met
- Compliance period
- 180 calendar days
- Period to regain compliance with each requirement
- Compliance deadline
- April 26, 2027
- Deadline stated for regaining compliance
- Required closing period
- 10 consecutive business days
- At or above the applicable threshold to regain compliance
Historical Context
-
Nasdaq cited an ADS closing bid below $1.00 for 30 consecutive business days.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The first Letter notified the Company that, based upon the Company's MVLS for the 30 consecutive business days from September 16, 2026 through October 27, 2026, the Company no longer meets the requirement under Nasdaq Listing Rule 5450(b)(2)(A) to maintain market value of listed securities ("MVLS") of at least
Pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180 calendar days, or until April 26, 2027, to regain compliance with the MVLS Requirement. If at any time during the compliance period the Company's MVLS closes at
The second Letter notified the Company that, based upon the Company's MVPHS for the 30 consecutive business days from September 16, 2026 through October 27, 2026, the Company no longer meets the requirement under Nasdaq Listing Rule 5450(b)(2&3)(C) to maintain a minimum market value of publicly held shares ("MVPHS") of
Pursuant to Nasdaq Listing Rule 5810(c)(3)(D), the Company has a compliance period of 180 calendar days, or until April 26, 2027, to regain compliance with the MVPHS Requirement. If at any time during the compliance period the Company's MVPHS closes at
If the Company does not regain compliance prior to the expiration of the applicable compliance period, the Company will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Hearings Panel.
The Company intends to monitor its MVLS and MVPHS and evaluate available options to regain compliance with the applicable continued listing requirements within the compliance period.
There can be no assurance that the Company will regain compliance with the applicable Nasdaq continued listing requirements within the compliance period or otherwise maintain compliance with Nasdaq's other continued listing requirements.
About POMDOCTOR LIMITED
POMDOCTOR LIMITED (Nasdaq: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include, without limitation, statements concerning the Company's ability and plans to regain and maintain compliance with Nasdaq's continued listing requirements, including the MVLS Requirement and the MVPHS Requirement, the Company's evaluation of alternatives available to regain compliance, and the continued listing of the Company's Class A ordinary shares on Nasdaq.
Forward-looking statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied by such statements. Factors that could cause actual results to differ materially include, among others, the Company's ability to regain and maintain compliance with the MVLS Requirement, the MVPHS Requirement and other Nasdaq continued listing requirements, fluctuations in the market price of the Company's Class A ordinary shares, and the other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission.
The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this press release, except as required by applicable law.
Investor Relations Contact
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-receipt-of-nasdaq-notifications-regarding-continued-listing-requirements-302925899.html
SOURCE POMDOCTOR LIMITED
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Pomdoctor (POM) receive Nasdaq listing deficiency notices?
Pomdoctor failed Nasdaq’s minimum market values of $50 million for listed securities and $15 million for publicly held shares. Both deficiencies covered 30 consecutive business days from September 16 through October 27, 2026. Nasdaq also identified noncompliance with Rule 5450(b)(3)(A).
What is Pomdoctor’s deadline to regain Nasdaq compliance?
Pomdoctor has 180 calendar days, until April 26, 2027, to regain compliance with both market-value requirements. Each value must close at or above its respective minimum for at least ten consecutive business days during the compliance period. Nasdaq would then provide written confirmation of compliance and close the applicable matter.
Can Pomdoctor appeal if Nasdaq issues a delisting determination?
Pomdoctor may appeal a delisting determination to a Hearings Panel. That option would become available after written notification that its securities are subject to delisting if it does not regain compliance before the applicable compliance period expires.